Market Size of Global Argatroban Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 3.50 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Argatroban Market Analysis
The argatroban market is expected to register a CAGR of 3.5% over the forecast period, 2022-2027.
The COVID-19 pandemic caused disruptions in the supply chains and treatment protocols for pharmaceuticals around the world, which also influenced the global anticoagulant, specific to the argatroban market. It also delays the research and development of medications for illnesses other than COVID-19. But the rate of thrombosis among COVID-19 hospitalized patients was found to be comparatively high early in the COVID-19 pandemic. In January 2021, Thorax, an international journal from BMJ published that COVID-19 patients may experience mild thrombocytopenia, mildly extended prothrombin time, increased fibrinogen, and elevated D-dimer that may lead to thrombosis. Thus COVID-19 had a significant impact on the market. Furthermore, it is anticipated that the market under study will eventually reach its full potential because of vaccination campaigns and a decline in COVID-19 cases.
Argatroban is a medicine used to prevent blood clots and helps in the improvement of neurological symptoms (motor paralysis) and activities of daily life (walking, standing, maintaining a sitting position, diet) associated with acute cerebral thrombosis. It is also used in the treatment of chronic arterial occlusion (Buerger's disease and arteriosclerosis obliterans), also as prophylaxis and for the prevention of heparin-induced thrombocytopenia (HIT) type II. In October 2020, the American Society of Hematology published that prothrombotic adverse drug reaction known as heparin-induced thrombocytopenia (HIT) can be observed in 0.1% to 7% of patients using heparin products, depending on patient population and type of heparin used in the medication. Heparin is necessary during routine hemodialysis in order to prevent clotting in the extracorporeal circuit. So, the argatroban is used to prevent the HIT in the hemodialysis patients. The other driving factor of argatroban market is the increased prevalence of cerebral venous thrombosis that can be observed in patients with HIT. In March 2022, American Heart Association published that 1.6% of people with HIT develop cerebral venous thrombosis. Hence, the increase in the prevalence of cerebral venous thrombosis may increase the growth of the argatroban market.
However, the side effects and related allergies of argatroban treatment is expected to restrain growth in the argatroban market during the forecast period of the study.
Argatroban Industry Segmentation
As per the scope of the report, argatroban is a direct thrombin inhibitor that prevents the clotting of blood. It is used in conditions such as Heparin-induced thrombocytopenia (HIT) and prevents blood coagulation during percutaneous coronary intervention. The Argatroban Market is segmented by Indication (Buerger's Disease, Arteriosclerosis Obliterans, Heparin-Induced Thrombocytopenia (HIT) Type II, Percutaneous Coronary Intervention and Other Indications), End User (Hospital Pharmacies, Retail Pharmacies, Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Indication | |
| Buerger's Disease | |
| Arteriosclerosis Obliterans | |
| Heparin-Induced Thrombocytopenia (HIT) | |
| Percutaneous Coronary Intervention | |
| Other Indications |
| By End User | |
| Hospital Pharmacies | |
| Retail Pharmacies | |
| Other End Users |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Argatroban Market Size Summary
The argatroban market is poised for steady growth, driven by its critical role in preventing blood clots and treating conditions such as acute cerebral thrombosis and chronic arterial occlusion. The drug's importance has been underscored by its use in preventing heparin-induced thrombocytopenia (HIT), a significant concern in patients undergoing hemodialysis. The market's expansion is further supported by the increasing prevalence of cerebral venous thrombosis, particularly among those with HIT. Despite the challenges posed by the COVID-19 pandemic, which disrupted supply chains and delayed research, the market is expected to recover and thrive as vaccination efforts reduce COVID-19 cases. The demand for argatroban is also influenced by the type of heparin used in clinical settings, impacting its market trajectory.
North America is anticipated to dominate the global argatroban market, fueled by the rising incidence of cardiovascular disorders and the development of new formulation products. The prevalence of conditions such as stroke, coronary artery disease, and peripheral artery disease, which are linked to thrombosis, underscores the drug's significance in the region. The market is characterized by its fragmented nature, with several key players like Mitsubishi Tanabe Pharma, AuroMedics Pharma LLC, and Pfizer Inc. actively participating. Regulatory approvals, such as those from the United States Food and Drug Administration, have further bolstered market confidence. As healthcare facilities resume operations and the prevalence of cardiovascular risk factors continues to rise, the argatroban market is expected to experience sustained growth over the forecast period.
Global Argatroban Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increased Use of Argatroban in Heparin-induced Thrombocytopenia
-
1.2.2 Increase in Prevalence of Cerebral Venous Thrombosis
-
-
1.3 Market Restraints
-
1.3.1 Side Effects and Related Allergies of Argatroban
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Indication
-
2.1.1 Buerger's Disease
-
2.1.2 Arteriosclerosis Obliterans
-
2.1.3 Heparin-Induced Thrombocytopenia (HIT)
-
2.1.4 Percutaneous Coronary Intervention
-
2.1.5 Other Indications
-
-
2.2 By End User
-
2.2.1 Hospital Pharmacies
-
2.2.2 Retail Pharmacies
-
2.2.3 Other End Users
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Global Argatroban Market Size FAQs
What is the current Global Argatroban Market size?
The Global Argatroban Market is projected to register a CAGR of 3.5% during the forecast period (2024-2029)
Who are the key players in Global Argatroban Market?
Mitsubishi Tanabe Pharma Corporation, AuroMedics Pharma LLC, Pfizer Inc, Viatris Inc and Hikma Pharmaceuticals PLC are the major companies operating in the Global Argatroban Market.
